Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease

Summary

The investigators intend to perform exploratory evaluation of the treatment effectiveness and safety of PM012 Tablet of PuriMED Co., Ltd. at 2 doses in Korean patients with mild to moderate dementia of Alzheimer's type. To achieve this, this study aims to compare each dose with placebo control for the efficacy and safety to explore the clinically optimal dose of PM012 Tablet for therapeutic confirmatory (phase 3) clinical studies.

Timeline

Start

2012-05

Primary completion

2014-09

Completion

2015-06

Drugs

Indications